The combination of the LAG3 inhibitor Relatlimab with Nivolumab is approved for treating metastatic melanoma, marking the debut of FDA-approved LAG3 monoclonal antibody combination therapy. The gene discussed is LAG3; the disease is metastatic melanoma.